The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
The importance of onco-geriatric assessments for multiple myeloma
Siobhan Glavey, MD, PhD, Royal College of Surgeons in Ireland, Dublin, Ireland, discusses the importance of utilizing geriatric assessments for elderly patients with multiple myeloma, as clinical trials indicate that clinical risk factors such as frailty are equally predictive of outcomes as cytogenetics. Prof. Glavey believes that frailty is a dynamic marker and should be assessed in combination with molecular analyses to provide better insights into which treatment option is appropriate for patients. This interview was recorded virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
